ArticleHuman vaccines & immunotherapeutics2026
Changes in 23-valent pneumococcal polysaccharide vaccination rate and associated factors in 2022 and 2024 among community-based older adults in Shanghai, China.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumococcal vaccination effectively reduces the incidence of pneumococcal pneumonia and the associated mortality rates in older adults. Understanding trends in coverage and the influencing factors is essential for optimizing future vaccination programs. Two cross-sectional surveys were conducted in October 2022 and September 2024 among residents aged 60 and above in Pudong New Area, Shanghai. Data on demographic characteristics, pneumococcal vaccination status, and reasons for either receiving or not receiving the vaccine were also collected. A generalized linear mixed model (GLMM) investigated temporal trends in vaccination rates, adjusting for sociodemographic factors. Interactions with the survey year were evaluated to identify associated with time-varying effects on vaccination. The pneumococcal vaccination rate was 34.8% (95% confidence interval [CI]: 32.9-36.6) in 2024, a significant increase of 10.6% points from 24.1% (95% CI: 22.4-25.8) in 2022. (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.